收稿日期: 2025-02-27
网络出版日期: 2025-08-28
基金资助
国家自然科学基金项目(82374591);四川省科技厅青年基金项目(24NSFSC7495)
Research progress on intestinal barrier in irritable bowel syndrome pathogenesis
Received date: 2025-02-27
Online published: 2025-08-28
何悦 , 程珂新 , 李艳秋 , 侯雨君 , 周思远 . 肠道屏障在肠易激综合征发病机制中的研究进展[J]. 实用医学杂志, 2025 , 41(16) : 2597 -2603 . DOI: 10.3969/j.issn.1006-5725.2025.16.023
Irritable bowel syndrome （IBS） is a prevalent functional gastrointestinal disorder characterized by a complex etiology involving multiple interacting factors. Accumulating evidence in recent years has indicated that intestinal barrier dysfunction may play a crucial role in the pathogenesis of IBS. This review systematically examines the impact of intestinal barrier dysfunction on IBS， analyzing its associations with the mechanical， immune， chemical， and microbial components of the gut barrier， as well as current clinical treatment approaches. Moreover， this paper highlights the potential of intestinal barrier repair mechanisms as therapeutic targets， which may provide novel insights and directions for understanding the underlying pathophysiological mechanisms and developing effective interventions for IBS.
| [1] | HUANG K Y， WANG F Y， LV M， et al. Irritable bowel syndrome： Epidemiology， overlap disorders， pathophysiology and treatment［J］. World J Gastroenterol， 2023， 29（26）： 4120-4135. doi:10.3748/wjg.v29.i26.4120 |
| [2] | IONESCU V A， GHEORGHE G， GEORGESCU T F， et al. The latest data concerning the etiology and pathogenesis of irritable bowel syndrome［J］. J Clin Med， 2024， 13（17）： 5124. doi:10.3390/jcm13175124 |
| [3] | CHEN Y， CUI W， LI X， et al. Interaction between commensal bacteria， immune response and the intestinal barrier in inflammatory bowel disease［J］. Front Immunol， 2021， 12： 761981. doi:10.3389/fimmu.2021.761981 |
| [4] | BARBARO M R， CREMON C， MARASCO G， et al. Molecular mechanisms underlying loss of vascular and epithelial integrity in irritable bowel syndrome［J］. Gastroenterology， 2024， 167（6）： 1152-1166. doi:10.1053/j.gastro.2024.07.004 |
| [5] | UNTERSMAYR E， BRANDT A， KOIDL L， et al. The intestinal barrier dysfunction as driving factor of inflammaging［J］. Nutrients， 2022， 14（5）： 949. doi:10.3390/nu14050949 |
| [6] | HANNING N， EDWINSON AL， CEULEERS H， et al. Intestinal barrier dysfunction in irritable bowel syndrome： A systematic review［J］. Therap Adv Gastroenterol， 2021， 14： 1756284821993586. doi:10.1177/1756284821993586 |
| [7] | SCHOULTZ I， KEITA ? V. The intestinal barrier and current techniques for the assessment of gut permeability［J］. Cells， 2020， 9（8）： 1909. doi:10.3390/cells9081909 |
| [8] | ZHAO D Y， QI Q Q， LONG X， et al. Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome［J］. Physiol Int， 2019， 106（3）： 225-235. doi:10.1556/2060.106.2019.20 |
| [9] | ZHAO J， DAI Y， TIAN J， et al. Impact of mechanical barrier damage and interleukin-17 on symptoms in patients with post-infectious irritable bowel syndrome［J］. Br J Hosp Med（Lond）， 2024， 85（7）： 1-13. doi:10.12968/hmed.2024.0114 |
| [10] | VENGE P， TEJERA V C， PETERSSON C， et al. Elevated fecal biomarkers of colo‐rectal epithelial cell activity in irritable bowel syndrome［J］.Neurogastroenterol Motil， 2025，37（4）：e14984. doi:10.1111/nmo.14984 |
| [11] | WANG J， ZHAO D， LEI Z， et al. TRIM27 maintains gut homeostasis by promoting intestinal stem cell self-renewal［J］. Cell Mol Immunol， 2023， 20（2）： 158-174. doi:10.1038/s41423-022-00963-1 |
| [12] | 许帮荣， 蒋正华， 陈鑫， 等. miRNA在肠黏膜屏障功能中的作用研究进展［J］. 实用医学杂志， 2025， 41（7）： 1079-1083. |
| [13] | XI M， ZHAO P， LI F， et al. MicroRNA-16 inhibits the TLR4/NF-κB pathway and maintains tight junction integrity in irritable bowel syndrome with diarrhea［J］.J Biol Chem， 2022， 298（11）： 102461. doi:10.1016/j.jbc.2022.102461 |
| [14] | XU R， LIU X， TIAN M， et al. Atractylodes-I overcomes the oxidative stress-induced colonic mucosal epithelial cells dysfunction to prevent irritable bowel syndrome via modulating the miR-34a-5p-LDHA signaling pathway［J］. Curr Mol Med， 2023， 23（8）： 825-833. doi:10.2174/1566524022666220811161111 |
| [15] | BALDA M S， MATTER K. Tight junctions［J］. Curr Biol， 2023， 33（21）： R1135-R1140. doi:10.1016/j.cub.2023.09.027 |
| [16] | MEOLI L， GüNZEL D. Channel functions of claudins in the organization of biological systemsclaudins［J］. Biochim Biophys Acta Biomembr， 2020， 1862（9）： 183344. doi:10.1016/j.bbamem.2020.183344 |
| [17] | AWAD K， BARMEYER C， BOJARSKI C， et al. Epithelial barrier dysfunction in diarrhea-predominant irritable bowel syndrome （IBS-D） via downregulation of claudin-1［J］. Cells， 2023， 12（24）： 2846. doi:10.3390/cells12242846 |
| [18] | 王玲玲， 柏茂树， 吴至久. 基于AQP3/claudin-1研究痛泻要方治疗腹泻型肠易激综合征模型大鼠的机制［J］. 辽宁中医杂志， 2024， 51（3）： 200-204， 229. |
| [19] | HORIE H， HANDA O， NAITO Y， et al. Subepithelial serotonin reduces small intestinal epithelial cell tightness via reduction of occluding expression［J］. Turk J Gastroenterol， 2022， 33（1）： 74-79. doi:10.5152/tjg.2022.20691 |
| [20] | YU S， HE J， XIE K. Zonula Occludens Proteins Signaling in Inflammation and Tumorigenesis［J］. Int J Biol Sci， 2023， 19（12）： 3804-3815. doi:10.7150/ijbs.85765 |
| [21] | HE Y Q， ZHU J R， SUN W J， et al. ZO-1 and IL-1RAP phosphorylation： Potential role in mediated brain-gut axis dysregulation in irritable bowel syndrome-like stressed mice［J］. Int J Med Sci， 2024， 21（9）： 1738-1755. doi:10.7150/ijms.95848 |
| [22] | LEE J Y， KIM N， PARK J H， et al. Expression of neurotrophic factors， tight junction proteins， and cytokines according to the irritable bowel syndrome subtype and sex［J］. J Neurogastroenterol Motil， 2020， 26（1）： 106-116. doi:10.5056/jnm19099 |
| [23] | KIM S U， CHOI J A， HAN M H， et al. Tight junction protein changes in irritable bowel syndrome： The relation of age and disease severity［J］. Korean J Int Med， 2024， 39（6）： 906-916. doi:10.3904/kjim.2024.097 |
| [24] | CHAI W H， MA Y， LI J J， et al. Immune cell signatures and causal association with irritable bowel syndrome： A mendelian randomization study［J］. World J Clinical Cases， 2024， 12（17）：3094-3104. doi:10.12998/wjcc.v12.i17.3094 |
| [25] | VAN REMOORTEL S， HUSSEIN H， BOECKXSTAENS G. Mast cell modulation： A novel therapeutic strategy for abdominal pain in irritable bowel syndrome［J］. Cell Rep Med， 2024， 5（10）： 101780. doi:10.1016/j.xcrm.2024.101780 |
| [26] | HASLER W L， GRABAUSKAS G， SINGH P， et al. Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome［J］. Neurogastroenterol Motil， 2022， 34（7）： e14339. doi:10.1111/nmo.14339 |
| [27] | MEIRA DE-FARIA F， CASADO-BEDMAR M， M?RTEN LINDQVIST C， et al. Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome［J］. Neurogastroenterol Motil， 2021， 33（11）： e14130. doi:10.1111/nmo.14130 |
| [28] | DECRAECKER L， ESTéVEZ M C， REMOORTEL S V， et al. Characterisation of MRGPRX2+ mast cells in irritable bowel syndrome［J］. Gut， 2025，74（7）：1068-1077. doi:10.1136/gutjnl-2024-334037 |
| [29] | KIM H J， KIM H， LEE J H， et al. Toll-like receptor 4 （TLR4）： New insight immune and aging［J］. Immun Ageing， 2023， 20（1）： 67. doi:10.1186/s12979-023-00383-3 |
| [30] | ZHOU G Q， HUANG M J， YU X， et al. Early life adverse exposures in irritable bowel syndrome： New insights and opportunities［J］. Front Pediatr， 2023， 11：124801. doi:10.3389/fped.2023.1241801 |
| [31] | WAN X， WANG L， WANG Z， et al. Toll-like receptor 4 plays a vital role in irritable bowel syndrome： A scoping review［J］. Front Immunol， 2024， 15： 1490653. doi:10.3389/fimmu.2024.1490653 |
| [32] | BELMONTE L， YOUMBA S B， BERTIAUX-VANDA?LE N， et al. Role of toll like receptors in irritable bowel syndrome： Differential mucosal immune activation according to the disease subtype［J］. PLoS One， 2012， 7（8）： e42777. doi:10.1371/journal.pone.0042777 |
| [33] | SHUKLA R， GHOSHAL U， RANJAN P， et al. Expression of toll-like receptors， pro-， and anti-inflammatory cytokines in relation to gut microbiota in irritable bowel syndrome： The evidence for its micro-organic basis［J］. J Neurogastroenterol Motil， 2018， 24（4）： 628-642. doi:10.5056/jnm18130 |
| [34] | SHIMBORI C， DE PALMA G， BAERG L， et al. Gut bacteria interact directly with colonic mast cells in a humanized mouse model of IBS［J］. Gut Microbes， 2022， 14（1）：2105095. doi:10.1080/19490976.2022.2105095 |
| [35] | ZHOU H H， ZHANG Y M， ZHANG S P， et al. Suppression of PTRF alleviates post-infectious irritable bowel syndrome via downregulation of the TLR4 pathway in rats［J］. Front Pharmacol， 2021， 12：724410. doi:10.3389/fphar.2021.724410 |
| [36] | MEYER F， WENDLING D， DEMOUGEOT C， et al. Cytokines and intestinal epithelial permeability： A systematic review［J］. Autoimmun Rev， 2023， 22（6）： 103331. doi:10.1016/j.autrev.2023.103331 |
| [37] | CRAWFORD C K， LOPEZ CERVANTES V， QUILICI M L， et al. Inflammatory cytokines directly disrupt the bovine intestinal epithelial barrier［J］. Sci Rep， 2022， 12（1）： 14578. doi:10.1038/s41598-022-18771-y |
| [38] | NORLIN A K， WALTER S， ICENHOUR A， et al. Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-α and mesocorticolimbic connectivity［J］. Brain Behav Immun， 2021， 92： 211-222. doi:10.1016/j.bbi.2020.11.035 |
| [39] | CHEN L J， PLANTINGA A M， BURR R， et al. Exploration of cytokines and microbiome among males and females with diarrhea-predominant irritable bowel syndrome［J］. Dig Dis Sci， 2025， 70（3）： 1043-1051. doi:10.1007/s10620-024-08836-5 |
| [40] | SANG X， WANG Q， NING Y， et al. Age-related mucus barrier dysfunction in mice is related to the changes in Muc2 mucin in the colon［J］. Nutrients， 2023， 15（8）： 1830. doi:10.3390/nu15081830 |
| [41] | XU Y， XIONG Y， LIU Y， et al. Activation of goblet cell Piezo1 alleviates mucus barrier damage in mice exposed to WAS by inhibiting H3K9me3 modification［J］. Cell Biosci， 2023， 13（1）： 7. doi:10.1186/s13578-023-00952-5 |
| [42] | ALONSO-COTONER C， ABRIL-GIL M， ALBERT-BAYO M， et al. The role of purported mucoprotectants in dealing with irritable bowel syndrome， functional diarrhea， and other chronic diarrheal disorders in adults［J］. Adv Ther， 2021， 38（5）： 2054-2076. doi:10.1007/s12325-021-01676-z |
| [43] | OKUMURA R， TAKEDA K. The role of the mucosal barrier system in maintaining gut symbiosis to prevent intestinal inflammation［J］. Semin Immunopathol， 2024， 47（1）： 2. doi:10.1007/s00281-024-01026-5 |
| [44] | FUSCO A， SAVIO V， DONNIACUO M， et al. Antimicrobial peptides human beta-defensin-2 and -3 protect the gut during candida albicans infections enhancing the intestinal barrier integrity： In vitro study［J］. Front Cell Infect Microbiol， 2021， 11：666900. doi:10.3389/fcimb.2021.666900 |
| [45] | SHULMAN R J， DEVARAJ S， HEITKEMPER M. Activation of the innate immune system in children with irritable bowel syndrome evidenced by increased fecal human β-defensin-2［J］. Clin Gastroenterol Hepatol， 2021， 19（10）： 2121-2127. doi:10.1016/j.cgh.2020.09.034 |
| [46] | SAPIB Z， DE PALMA G， LU J， et al. Alterations in fecal β-defensin-3 secretion as a marker of instability of the gut microbiota［J］. Gut Microbes， 2023， 15（1）： 2233679. doi:10.1080/19490976.2023.2233679 |
| [47] | CHOPYK D M， GRAKOUI A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders［J］. Gastroenterology， 2020， 159（3）： 849-863. doi:10.1053/j.gastro.2020.04.077 |
| [48] | PARDO-CAMACHO C， GANDA MALL J P， MARTíNEZ C， et al. Mucosal plasma cell activation and proximity to nerve fibres are associated with glycocalyx reduction in diarrhoea-predominant irritable bowel syndrome： Jejunal barrier alterations underlying clinical manifestations［J］. Cells， 2022， 11（13）： 2046. doi:10.3390/cells11132046 |
| [49] | HOU J J， WANG X， LI Y， et al. The relationship between gut microbiota and proteolytic activity in irritable bowel syndrome［J］. Microb Pathog， 2021， 157： 104995. doi:10.1016/j.micpath.2021.104995 |
| [50] | SU Q， TUN H M， LIU Q， et al. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome［J］. Gut Microbes， 15（1）： 2157697. doi:10.1080/19490976.2022.2157697 |
| [51] | 窦鑫， 贺昌辉， 梅笑， 等. 基于“短链脂肪酸-肠屏障”途径探讨中药在腹泻型肠易激综合征中的干预研究进展［J］. 实用医学杂志， 2024， 40（15）： 2177-2182. |
| [52] | EL-SALHY M， VALEUR J， HAUSKEN T， et al. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome［J］. Neurogastroenterol Motil， 2021， 33（2）： e13983. doi:10.1111/nmo.13983 |
| [53] | TEIGE E S， HILLESTAD E M R， STEINSVIK E K， et al. Fecal bacteria and short-chain fatty acids in irritable bowel syndrome： Relations to subtype［J］. Neurogastroenterol Motil， 2024， 36（9）： e14854. doi:10.1111/nmo.14854 |
| [54] | WU B Y， XU P， CHENG L， et al. The alteration of mucosal bile acid profile is associated with nerve growth factor expression in mast cells and bowel symptoms in diarrhea-predominant irritable bowel syndrome［J］. Clin Exp Immunol， 2024， 216（2）： 200-210. doi:10.1093/cei/uxae006 |
| [55] | YU L M， MAO L Q， WU C Y， et al. Chlorogenic acid improves intestinal barrier function by downregulating CD14 to inhibit the NF-κB signaling pathway［J］. J Funct Foods， 2021， 85： 104640. doi:10.1016/j.jff.2021.104640 |
| [56] | LINSALATA M， RIEZZO G， ORLANDO A， et al. The role of intestinal barrier function in overweight patients with IBS with diarrhea undergoing a long-term low fermentable oligo-， di-， and monosaccharide and polyol diet［J］. Nutrients， 2023， 15（21）： 4683. doi:10.3390/nu15214683 |
| [57] | NEE J， LEMBO A. Review article： Current and future treatment approaches for IBS with diarrhoea （IBS‐D） and IBS mixed pattern （IBS‐M）［J］.Aliment Pharmacol Ther， 2021，54（）：S63-S74. doi:10.1111/apt.16625 |
| [58] | ZHEN Z， XIA L， YOU H， et al. An integrated gut microbiota and network pharmacology study on fuzi-lizhong pill for treating diarrhea-predominant irritable bowel syndrome［J］. Front Pharmacol， 2021， 12：746923. doi:10.3389/fphar.2021.746923 |
| [59] | MA X， HUANG J， WU H， et al. Uncovering the multitarget therapeutic mechanism of tong‐xie‐yao‐fang on irritable bowel syndrome［J］.J Food Qual，2024，2024（1）：8195739. doi:10.1155/2024/8195739 |
| [60] | HOU Y， CHANG X， LIU N， et al. Different acupuncture and moxibustion therapies in the treatment of IBS-D with anxiety and depression： A network meta-analysis［J］. Medicine（Baltimore）， 2024， 103（17）： e37982. doi:10.1097/md.0000000000037982 |
| [61] | FU Y， DING X， ZHANG M， et al. Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor［J］. Nat Biotechnol， 2024. doi： 10.1038/s41587-024-02503-w . Epub ahead of print. |
/
| 〈 |
|
〉 |